CoChat

Effectiveness of V-Go(®) for patients with type 2 diabetes in a real-world setting: A prospective observational study

Open access

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

BACKGROUND: V-Go is a wearable, patch-like, 24-h insulin delivery device that delivers both a continuous preset basal rate and on-demand bolus dosing. The aim of this study was to observe glycemic control, insulin dosing, and hypoglycemia risk in patients switched to V-Go in a real-world setting. The primary objective was to compare change in mean hemoglobin A1c (HbA1c) from baseline to the end of V-Go use. METHODS: This prospective, open-label, multicenter study recruited patients with type 2 diabetes (T2D) and suboptimal glycemic control (HbA1c ≥ 7%) across 28 centers. Efficacy analyses were conducted for all patients with a post-baseline HbA1c and results stratified based on prior antihyperglycemic medication therapies. Insulin dosing was at the discretion of the health care provider and the protocol did not mandate glycemic targets. Treatment satisfaction surveys were utilized to gain patient feedback on the use of V-Go. RESULTS: One hundred eighty-eight patients were enrolled in the study, among whom 140 patients had a valid post-baseline HbA1c and were included in the primary efficacy analysis. Use of V-Go resulted in a change of - 0.64%; (P = 0.003) in HbA1c from baseline, and in those prescribed insulin, the total daily dose of insulin was decreased by 12 units/day (P < 0.0001). Twenty-two patients (12%) reported hypoglycemic events (≤ 70 mg/dL), with an event rate of 1.51 events/patient/year. CONCLUSION: In a T2D population with suboptimal HbA1c, initiating V-Go therapy in a real-world setting significantly improved glycemic control and led to significant insulin dose reductions. ClinicalTrial.gov registry identifier: NCT01326598.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40801-019-00173-8

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Comparison of change in HbA1c over time by strata and V-Go use. a Mean HbA1c from screening to month 6; b HbA1c for all patients using V-Go vs. patients discontinuing V-Go; c mean total daily dose from screening to month 6; d total daily dose of all patients using V-Go vs. patients discontinuing V-Go. Stratum 3 (S3) = once/twice-daily long-acting insulin injection ± OADs/non-insulin injectable; stratum 4 (S4) = 1–3 daily premix insulin injections ± OADs/ non-insulin injectable; and stratum 5 (S5) = multiple daily injection (MDI) therapy with 3+ daily insulin injections ± OADs/non-insulin injectable. OADs oral antihyperglycemic drugs
Fig. 1 Comparison of change in HbA1c over time by strata and V-Go use. a Mean HbA1c from screening to month 6; b HbA1c for all patients using V-Go vs. patients discontinuing V-Go; c mean total daily dose from screening to month 6; d total daily dose of all patients using V-Go vs. patients discontinuing V-Go. Stratum 3 (S3) = once/twice-daily long-acting insulin injection ± OADs/non-insulin injectable; stratum 4 (S4) = 1–3 daily premix insulin injections ± OADs/ non-insulin injectable; and stratum 5 (S5) = multiple daily injection (MDI) therapy with 3+ daily insulin injections ± OADs/non-insulin injectable. OADs oral antihyperglycemic drugsCC BY · PubMed Central
Fig. 2 Comparison of change in HbA1c from baseline in patients from strata 3, 4, 5 who were using V-Go at month 6 versus patients who discontinued V-Go and resumed other antihyperglycemic therapies for 6 months. Stratum 3 (S3) = once/twice-daily long-acting insulin injection ± OADs/non-insulin injectable; stratum 4 (S4) = 1–3 daily premix insulin injections ± OADs/non-insulin injectable; and stratum 5 (S5) = multiple daily injection (MDI) therapy with 3+ daily insulin injections ± OADs/non-insulin injectable. *For patients who discontinued V-Go, month numbers were grouped into 3-month intervals for the purposes of summarization. OADs oral antihyperglycemic drugs
Fig. 2 Comparison of change in HbA1c from baseline in patients from strata 3, 4, 5 who were using V-Go at month 6 versus patients who discontinued V-Go and resumed other antihyperglycemic therapies for 6 months. Stratum 3 (S3) = once/twice-daily long-acting insulin injection ± OADs/non-insulin injectable; stratum 4 (S4) = 1–3 daily premix insulin injections ± OADs/non-insulin injectable; and stratum 5 (S5) = multiple daily injection (MDI) therapy with 3+ daily insulin injections ± OADs/non-insulin injectable. *For patients who discontinued V-Go, month numbers were grouped into 3-month intervals for the purposes of summarization. OADs oral antihyperglycemic drugsCC BY · PubMed Central
Fig. 3 Patient treatment satisfaction ratings for V-Go. Patients (N = 171) answered questions by assigning a value on a scale of 1–10 (with 1 being the worst and 10 being the best) from month 1 of the study to the end of the study. All patient surveys are included, regardless of the completion of the study or the continued use of V-Go
Fig. 3 Patient treatment satisfaction ratings for V-Go. Patients (N = 171) answered questions by assigning a value on a scale of 1–10 (with 1 being the worst and 10 being the best) from month 1 of the study to the end of the study. All patient surveys are included, regardless of the completion of the study or the continued use of V-GoCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 19

Metadata

Authors
Grunberger, G., Rosenfeld, C. R., Bode, B. W., Abbott, S. D., Nikkel, C., Shi, L., & Strange, P.
Affiliations
  • Oakland University (US)
  • Touro College (US)
  • Atlanta Diabetes Associates (US)
Corresponding author
Nikkel, Carla
Venue
Drugs - Real World Outcomes
Published
2019-12-12
Volume
7
Issue
1
Pages
31-40
ISSN
  • 2198-9788 (ISSN-L)
  • 2199-1154
OpenAlex
W2995327439
Cited by
19
References
17
Citations by year
2026: 2 · 2025: 2 · 2024: 6 · 2023: 3 · 2022: 3 · 2021: 1 · 2020: 2
FWCI
1.22
Type
journal article
Language
en
Open access
Licence
Locations
  • Drugs - Real World Outcomes (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Touro Scholar (Touro College) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Valeritas
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords
type 2 diabetes, continuous insulin infusion, glycemic control, HbA1c, insulin dose reduction, hypoglycemia, multiple daily insulin injections, treatment satisfaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness of V-Go(®) for patients with type 2 diabetes in a real-world setting: A prospective observational study. https://app.cochat.ai/papers/10.1007/s40801-019-00173-8
The paper
Grunberger, G., Rosenfeld, C. R., Bode, B. W., Abbott, S. D., Nikkel, C., Shi, L., & Strange, P. (2020). Effectiveness of V-Go(®) for patients with type 2 diabetes in a real-world setting: A prospective observational study. Drugs - Real World Outcomes. https://doi.org/10.1007/s40801-019-00173-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.